PDF(Pubmed)
Abstract：
The widespread administration of COVID-19 vaccines has prompted a need to understand their safety profile. This investigation focuses on the safety of inactivated and mRNA-based COVID-19 vaccines, particularly concerning potential cardiovascular and haematological adverse events. A retrospective cohort study was conducted for 1.3 million individuals residing in Abu Dhabi, United Arab Emirates, who received 1.8 million doses of the inactivated BBIBP CorV (by SinoPharm) and mRNA-based BNT162b2 (Pfizer-BioNTech) vaccines between June 1, 2021, and June 30, 2022. The study\'s primary outcome was to assess the occurrence of selected cardiovascular and haematological events leading to hospitalization or emergency room visits within 21 days post-vaccination. Results showed no significant increase in the incidence rates of these events compared to the subsequent 22 to 42 days following vaccination. Analysis revealed no elevated risk for adverse outcomes following first (IRR 1·03; 95% CI 0·82-1·31), second (IRR 0·92; 95% CI 0·72-1·16) and third (IRR 0·82; 95% CI 0·66-1·00) doses of either vaccine. This study found no substantial link between receiving either mRNA and inactivated COVID-19 vaccines and a higher likelihood of cardiovascular or haematological events within 21 days after vaccination.
摘要：
COVID-19疫苗的广泛使用促使人们需要了解其安全性。这项调查的重点是灭活和基于mRNA的COVID-19疫苗的安全性，特别是潜在的心血管和血液学不良事件。对居住在阿布扎比的130万人进行了一项回顾性队列研究。阿拉伯联合酋长国,在2021年6月1日至2022年6月30日之间，他们接受了180万剂灭活的BBIBPCorV（由SinoPharm提供）和基于mRNA的BNT162b2（Pfizer-BioNTech）疫苗。该研究的主要结果是评估接种疫苗后21天内导致住院或急诊室就诊的选定心血管和血液学事件的发生情况。结果显示，与疫苗接种后的22至42天相比，这些事件的发生率没有显着增加。分析显示，首次治疗后不良结局的风险没有升高(IRR1·03；95%CI0·82-1·31)，两种疫苗的第二剂(IRR0·92;95%CI0·72-1·16)和第三剂(IRR0·82;95%CI0·66-1·00)。这项研究发现，接受mRNA和灭活的COVID-19疫苗与接种后21天内发生心血管或血液学事件的可能性更高之间没有实质性联系。
